Login
← Go Back
Glenmark Pharmaceuticals
GLENMARK · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Glenn Saldanha · Listing date: Feb. 9, 2000 · Employees: 10964 · Mumbai · http://www.glenmarkpharma.com
Stock Price vs Company Growth
1d
1.9%
1w
2.0%
1m
10.7%
3m
13.7%
6m
29.6%
1y
94.4%
5y
35.2%
10y
6.6%
all
9.7%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 1,495 1.9%
1,452
1,830
Company Overview
Sales
12,248 Cr
Growth: 1.0%
Profit after Tax
-875 Cr
Growth: -33.3%
Large Cap
42,189 Cr
P/S: 3.4x
Industry P/S: 3.2x
Fundamentals
Sales (Cr) ₹ 12,248
Growth 1.0%
EBITDA 12.1%
P/S 3.4x
Dividend 0.3%
P/E -41.4x
Book Value ₹ 303
PEG Ratio -41.5x
ROE -10.4%
P/B 5.0x
Shareholding Pattern
Institutions
Qualified Institutional Buyer
4.74 %
Hsbc Pooled Investment Fund - Hsbc Pooled Asia Pac
3.25 %
Hdfc Trustee Company Ltd. A/C Hdfc Growth Opportunities Fund
2.26 %
Ntasain Discovery Master Fund
2.05 %
Life Insurance Corporation Of India
1.76 %
Promoters
Saldanha Family Trust
45.45 %
Blanche Elizabeth Saldanha
0.39 %
Glenn Mario Saldanha
0.35 %
Cherylann Maria Pinto
0.27 %
Robin Joseph Pinto
0.18 %
Others
Ashish Dhawan
1.81 %
Iepf
0.08 %
Increase    Decrease    No change
Company Profile Detailed
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain].
Belongs to (24 Indices) view more
Investors (108)
setu.sec...
tata.bal...
robin.pi...
Followers (36)
nitin2
keerthi
deepak